Get started
Author

Kolette D. Fly

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
2013 · R J Motzer, B Escudier, et al. · British Journal of Cancer · 133
PDF
Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment‐use trial of sunitinib
2015 · Peter Reichardt, Yoon‐Koo Kang, et al. · Cancer · 109
Long‐term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome‐positive leukemias treated with bosutinib
2016 · Jorge E. Cortes, H. Jean Khoury, et al. · American Journal of Hematology · 96
PDF
Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer
2002 · A. Buzdar, D. Hayes, et al. · Breast Cancer Research and Treatment · 67
First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas
2020 · Ajay K. Gopal, Ronald Levy, et al. · Clinical Cancer Research · 66
Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial
2016 · Peter Reichardt, George D. Demetri, et al. · BMC Cancer · 66
PDF
Safety and Efficacy of Sunitinib in Patients from Italy with Metastatic Renal Cell Carcinoma: Final Results from an Expanded-Access Trial
2015 · Cora N. Sternberg, Fabio Calabrò, et al. · Oncology · 28
Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer
2022 · David S. Hong, Ajay K. Gopal, et al. · Frontiers in Immunology · 20
Long-term evaluation of vascular toxicity in patients with Ph+ leukemias treated with bosutinib.
2014 · Jorge E. Cortes, Hagop M. Kantarjian, et al. · Journal of Clinical Oncology · 14
Neuro/medical Oncology
2013 · P. Ambady, M. Holdhoff, et al. · Neuro-Oncology · 8
PDF
Final toxicity results of a phase I dose-escalation trial of tremelimumab (CP-675206) in combination with gemcitabine in chemotherapy-naive patients (pts) with metastatic pancreatic cancer.
2011 · M. Aglietta, C. Barone, et al. · Journal of Clinical Oncology · 5
A phase I dose escalation trial of CP-675206 (tremelimumab) in combination with gemcitabine in patients with chemotherapy-naive metastatic pancreatic cancer.
2010 · M. Aglietta, C. Barone, et al. · Journal of Clinical Oncology · 5
Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
2017 · Robert W. Chen, Stephen Maxted Ansell, et al. · Journal of Clinical Oncology · 3
Continued Sunitinib Treatment After Progressive Disease (PD) in a Worldwide Treatment-Use Trial of Patients (PTS) With Gastrointestinal Stromal Tumor (GIST)
2012 · P. Reichardt, Y. Kang, et al. · Annals of Oncology · 3
9421 POSTER Optimizing Management of Sunitinib Treatment in a Worldwide Treatment-use Trial of Patients (Pts) With Advanced Gastrointestinal Stromal Tumour (GIST)
2011 · P. Reichardt, Y.K. Kang, et al. · European Journal of Cancer · 2
Correlation of KIT and PDGFRA mutational status with clinical benefit in patients (pts) with gastrointestinal stromal tumor (GIST) treated with sunitinib (SU) in a worldwide treatment-use (TU) trial.
2014 · Peter Reichardt, George D. Demetri, et al. · Journal of Clinical Oncology · 1
A phase I study of CD40 agonist monoclonal antibody (CP-870,893) with gemcitabine in pancreatic cancer.
2010 · G. L. Beatty, E. G. Chiorean, et al. · Journal of Clinical Oncology · 1
Table S2 from First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas
2023 · Ajay K. Gopal, Ronald Levy, et al.
Table S2 from First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas
2023 · Ajay K. Gopal, Ronald Levy, et al.
PDF
Supplementary Figure S3 from First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas
2023 · Ajay K. Gopal, Ronald Levy, et al.
Supplementary Figure S2 from First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas
2023 · Ajay K. Gopal, Ronald Levy, et al.
PDF
Supplementary Figure S1 from First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas
2023 · Ajay K. Gopal, Ronald Levy, et al.
Table S1 from First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas
2023 · Ajay K. Gopal, Ronald Levy, et al.
PDF
Table S1 from First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas
2023 · Ajay K. Gopal, Ronald Levy, et al.
Supplementary Figure S2 from First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas
2023 · Ajay K. Gopal, Ronald Levy, et al.
Works count: 30
Citation count: 627
H-index: 9
I10-index: 9
Year
Topic
Type